Pediatric Neuroblastoma Treatment Market – Overview
Pediatric neuroblastoma is a rare form of cancer which accounts for nearly 10% of all tumors in children. Pediatric neuroblastoma affects around 1,200 children in Europe and the U.S. each year. Neuroblastoma from primitive sympathetic ganglion cells found in the adrenal medulla or from other parts. Nearly 700 new cases of pediatric neuroblastoma are diagnosed in the U.S. each year, of these 90% patients are diagnosed before five years of age. According to the American Cancer Society, childhood cancer diagnosis rate is less than 1% of all types of cancers diagnosed each year.
The treatment and prognosis of individuals suffering from neuroblastoma depend on various biological and clinical factors such as age of the individual, disease stage, amplification of the MYCN oncogene, and histology. The risk levels of pediatric neuroblastoma are determined based on the above mentioned prognostic factors. The survival rate of individuals with low risk tumors is high. Individuals suffering with intermediate risk neuroblastoma have a survival rate of approximately 95%, following chemotherapy which varies in duration and intensity depending upon the risk factors associated prior to surgical resection. The average number of individuals with high risk of neuroblastoma is nearly 250 to 300 for each year. The treatment comprises intense chemotherapy, in certain cases autologous stem cell transplantation, and localized radiation. During the course, a six-month immunotherapy is also considered using dinutuximab and anti-GD2 antibody treatment in combination with GM-CSF and IL-2, administered in interchanging cycles and retinoic acid.
Increase in research activity in also expected to drive the global pediatric neuroblastoma treatment market during the forecast period. Launch of highly efficient and improved products, technological innovation, and rise in disease incidence and prevalence rate contribute to the growth of the global pediatric neuroblastoma treatment market during the forecast period. In 2015, United Therapeutics’ anti-GD2 antibody received approval from the EMA for the treatment of neuroblastoma in individuals aged between 12 months and 17 years. In the past few years, newer and more efficient therapies have been developed using advance technology. For example, in 2017, the European Commission granted marketing approval to Apeiron Biologic’s molecule APN311 to be used in rare pediatric neuroblastoma. The antibody is manufactured with CHO cells, which have a higher safety profile when compared to previous antibody based therapies. Government initiation to promote disease awareness and treatment is also expected to propel the global pediatric neuroblastoma market. Major restraints of the market are lack of approved treatment, high cost of treatment, and low levels of awareness in developing economies.
Request to View TOC of Report –
Geographically, the global pediatric neuroblastoma treatment market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to account for the largest share of the global market during the forecast period primarily due to higher awareness about the disease, better health care infrastructure for pediatric care, and presence of approved treatment for pediatric neuroblastoma. Europe is the second largest market for pediatric neuroblastoma treatment. The pediatric neuroblastoma market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to rise in awareness, increase in research and development in the region, and improvement in health care infrastructure. The market in Latin America and Middle East & Africa is expected to grow at a moderate rate during the forecast period.
Only a few pharmaceutical manufacturers such as United Therapeutics Corp. and APEIRON Biologics AG have approved treatment for pediatric neuroblastoma.
Request to View Discount –